glp-1 gastric intestinal obstruction lawsuit in louisiana lawyer semaglutide gi obstruction law office louisiana Ozempic Information-mvanhaasteren.nl glp-1 gastric intestinal obstruction lawsuit
Description
WEGOVY(semaglutide) injection 2.4 mg is an injectable prescription medicine that may help adults and children aged 12 years with obesity (BMI 30 for adults, BMI 95th percentile for age and sex for children), or some adults with excess weight (BMI 27) (overweight) who also have weight-related medical problems to
Suggested Use: Take 2 gummies daily with food or as recommended by your healthcare practitioner
In a 12-week human trial, participants achieved on average
Gastrointestinal (GI) adverse eventsparticularly nausea, vomiting, diarrhea, and constipationare the most common side effects, generally emerging during dose escalation and resolving over time
Key Benefits: No injections required
95% CI: 0.321.00), though no significant effect was found on all-cause mortality (HR 0.81
